|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
(1) The frequencies of B*51:01, DRB1*07:01, DQB1*02:01, A*01:01-C*06:02, A*01:01-DRB1*07:01, C*06:02-DQB1*02:01, DRB1*07:01-DQB1*02:01 and C*06:02-DRB1*07:01-DQB1*02:01 in cancer group were higher than control group whereas the frequencies of B*44:02, B*58:01, C*05:01, DRB1*04:01, DRB1*12:01, DRB1*13:01, DQB1*02:02, DQB1*05:02, DRB1*03:01-DQB1*02:02 and DRB1*04:01-DQB1*03:02 in cancer group were lower than control group (P < 0.05).
|
29356954 |
2018 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
An HPV16-E7/HLA-DRB1*04 TCR has been isolated from a cancer patient with complete response, and retroviral particles encoding this TCR have been produced.
|
30136612 |
2018 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
We highlight two major aspects of this case: (1) the unusual occurrence of early PTLD involving the cardiac allograft and causing a fatal outcome, (2) the application of an immunological technique for HLA-DRB1 typing to posttransplant paraffin-embedded autopsy material to identify the recipient origin of this early malignancy, thus excluding a possible donor-transmitted neoplasm.
|
23331771 |
2013 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
HLA-DRB1*0403 allele was also associated with a significantly increased risk of high-grade squamous intraepithelial lesion or cancer, showing a multivariate-adjusted hazard ratio (95% CI) of 18.1 (2.6-128.5).
|
21692064 |
2012 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
We investigated the association of human leukocyte antigen (HLA) II (DRB1 and DQB1) alleles with susceptibility to human papillomavirus (HPV)-associated cervical precancer and cancer cases in a hospital-based case-control study in a northern Indian population.
|
19272325 |
2009 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
The risk of mortality due to ischemic heart disease or cancer in RA is increased in patients carrying HLA-DRB1 genotypes with particular homozygous and compound heterozygous SE combinations.
|
17469097 |
2007 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
In summary, the DRB1*01 genotype may be correlated to a higher risk for malignancy.
|
15585555 |
2005 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
Recently, the HLA class II alleles DRB1* 11 and DQB1* 03 have been found to be significantly increased for patients with sporadic MF, suggesting a possible immunogenetic basis for the pathogenesis of this malignancy.
|
15761416 |
2005 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
Compared with women who were HPV negative, women with HLA-DRB1*1301 were associated with decreased risk for cancer/HSILs (odds ratio [OR], 0.4; 95% confidence interval [CI], 0.2-0.7) and for LSILs/HPV (OR, 0.6; 95% CI, 0.3-0.9).
|
11679920 |
2001 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
After correction for multiple testing, only the DQB1*0602 and the DRB1*1501 alleles remain associated with cancer and only in HPV16-infected patients (DQB1*0602: 102/264 (39%) vs. 130/476 (28%), p = 0.028 and DRB1*1501: 104/259 (40%) vs. 132/469 (28%), p = 0.027).
|
11519043 |
2001 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Increased frequency of HLA class II alleles DRB1*0301 and DQB1*0201 in Lambert-Eaton myasthenic syndrome without associated cancer.
|
10980394 |
2000 |
|
HLA-DRB1
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation |
BEFREE |
HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy.
|
7558926 |
1995 |